Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection
Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.
How this was made
The 30-second read
Why it matters
The quarter’s mix shift toward higher-margin oncology and faster-growing data licensing bookings supports the profitability narrative, while the Personalis deal and reimbursement milestones define the next set of estimate revisions and risk premium changes.
Market read
Traders can update near-term expectations around FY guidance, reimbursement-driven ASP uplift timing, and deal-related integration risk that may affect valuation and volatility.
What to watch
Personalis integration could create near-term margin dilution and execution risk; also, the oncology ASP stability is mix-dependent, with MRD volume exclusions potentially masking underlying pricing pressure.
Background
Tempus is positioning its oncology diagnostics and AI data platform toward scaled profitability, with a major step-up expected from reimbursement improvements and the planned acquisition of Personalis to own the NeXT Personal MRD assay.
Ticker impact
Tempus reported Q3 2026 revenue growth to $411.5M, raised FY revenue guidance to $1.60B-$1.605B, and detailed a pending $1.7B Personalis acquisition.
Likely positive bias as investors price in guidance raise and accelerating oncology and licensing, tempered by integration and GAAP profitability concerns.
The article contains multiple company-specific, decision-relevant disclosures: quarterly results with adjusted EBITDA inflection, explicit FY guidance raise, and deal terms plus timing that affect forward estimates and risk.
Market effects
Reinforces investor focus on oncology diagnostics scale, AI data licensing traction, and reimbursement-driven adoption as key profitability levers in precision medicine.
Primarily US-listed healthcare/biotech sentiment; limited direct regional spillover beyond US growth-tech healthcare.
Partnership and FDA-approval pathways highlight US regulatory and reimbursement dynamics that can influence global precision oncology adoption narratives.
Counterpoint
The adjusted EBITDA improvement may be less durable if reimbursement improvements slip, while GAAP operating losses and concentration in a few pharma relationships could cap multiple expansion.
Key entities
- companyTempus AI, Inc.
NASDAQ-listed oncology diagnostics and AI data licensing company reporting Q3 2026 results and raising FY 2026 revenue guidance.
- companyPersonalis
Target in a pending acquisition valued around $1.7B, bringing full ownership of the NeXT Personal MRD assay.
- companyBristol Myers Squibb
Partner referenced for a multi-year data and applications licensing collaboration valued up to $137.5M over five years.
- companyAstraZeneca
Pharmaceutical partner referenced for acceptance of Tempus’s oncology foundation model on response prediction tasks.
